Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,280
-1,800 (-9.43%)
At close: Dec 5, 2025
Market Cap 768.78B
Revenue (ttm) 46.65B
Net Income (ttm) 16.75B
Shares Out 44.49M
EPS (ttm) n/a
PE Ratio 45.89
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,700,974
Average Volume 4,992,096
Open 19,380
Previous Close 19,080
Day's Range 16,800 - 19,800
52-Week Range 3,138 - 26,600
Beta n/a
RSI 51.36
Earnings Date Nov 11, 2025

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.